Prosecution Insights
Last updated: April 19, 2026
Application No. 18/380,245

Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition

Non-Final OA §102§112
Filed
Oct 16, 2023
Examiner
ANDERSON, JAMES D
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sistema Universitario Ana G Mendez Inc.
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
2y 12m
To Grant
74%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allow Rate
729 granted / 1321 resolved
-4.8% vs TC avg
Strong +19% interview lift
Without
With
+19.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 12m
Avg Prosecution
37 currently pending
Career history
1358
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
27.8%
-12.2% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
30.7%
-9.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1321 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Formal Matters Claims 1-2 were originally presented on 10/16/2023 and are pending and under examination. Priority This application is a DIV of 17/343,503, filed 06/09/2021, which is a CON of 16/853,412, filed 04/20/2020, which is a CON of 15/895,783, filed 02/13/2018, which is a CIP of 14/857,500, filed 09/17/2015, which claims the benefit of PRO 62/121,157, filed 02/26/2015, and PRO 62/051,875, filed 09/17/2014. Information Disclosure Statement No Information Disclosure Statements have been filed. Claim Objections Claims 1 and 2 are objected to because of the following informalities: the steps of the claims, e.g., “a.”, “b.”, etc. should be written as “a)” or “(a)”. Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. "The primary purpose of this requirement of definiteness of claim language is to ensure that the scope of the claims is clear so the public is informed of the boundaries of what constitutes infringement of the patent. A secondary purpose is to provide a clear measure of what applicants regard as the invention so that it can be determined whether the claimed invention meets all the criteria for patentability and whether the specification meets the criteria of 35 U.S.C. 112, first paragraph with respect to the claimed invention.", (see MPEP § 2173). Claims 1-2 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 and 2 recite synthesis procedures for a benzazolo[3,2-a]quinolinium chloride salt comprising multiple synthetic steps. In step a), a 2-aminoacetanilide is formed by reacting a mixture of o-phenylenediamine and ethyl acetate. Step b) requires reacting a second mixture “…comprising a 2-aminoacetanilide and a benzaldehyde of formula…” The metes and bounds of the claims are unclear because “a 2-aminoacetanilide” as recited in step b) is ambiguous. It is unclear whether this is intended to be limited to the 2-aminoacetanilide formed in step a) or can more broadly encompass any 2-aminoacetanilide, e.g., a substituted 2-aminoacetanilide. Other steps of the claims clearly require reacting mixtures comprising a compound formed in the previous step by reciting “…said [compound from previous step]…” Step b), in contrast, does not recite “…said 2-aminoacetanilide…”, rendering it unclear whether this 2-aminoacetanilide is the 2-aminoacetanilide formed in the prior step. The Examiner suggests amending step b) of each of claims 1 and 2 to recite “…the 2-aminoacetanilide…” or “…said 2-aminoacetanilide…” to clearly convey that the 2-aminoacetanilide in step b) is the same 2-aminoacetanilide formed in step a). Citation of Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US Patent No. 4,590,275 US Patent No. 8,124,770 US Patent No. 9,085,574 US Patent No. 9,889,128 US Patent No. 10,624,885 US Patent No. 11,311,531 US Patent No. 11,786,520 Conclusion Applicant is requested to specifically point out the support for any amendments made to the disclosure in response to this Office action, including the claims (M.P.E.P. §§ 714.02 and 2163.06). In doing so, applicant is requested to refer to pages and line (or paragraph) numbers (if available) in the as-filed specification, not the published application. Due to the procedure outlined in M.P.E.P. § 2163.06 for interpreting claims, other art may be applicable under 35 U.S.C. § 102 or 35 U.S.C. § 103(a) once the aforementioned issue(s) is/are addressed. Applicant is reminded that MPEP §2001.06(b) clearly states that “[t]he individuals covered by 37 C.F.R. 1.56 have a duty to bring to the attention of the examiner, or other Office official involved with the examination of a particular application, information within their knowledge as to other copending United States applications which are "material to patentability" of the application in question." See Armour & Co. v. Swift & Co., 466 F.2d 767, 779, 175 USPQ 70, 79 (7th Cir. 1972). MPEP §2001.06(b) clearly indicates that “if a particular inventor has different applications pending in which similar subject matter but patentably indistinct claims are present that fact must be disclosed to the examiner of each of the involved applications.” See Dayco Prod. Inc. v. Total Containment, Inc., 329 F.3d 1358, 1365-69, 66 USPQ2d 1801, 1806-08 (Fed. Cir. 2003). Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES D ANDERSON whose telephone number is (571)272-9038. The examiner can normally be reached on Monday-Friday, 7:30 am - 4:00 pm PST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached on 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /James D. Anderson/Primary Examiner, Art Unit 1629 UNITED STATES PATENT AND TRADEMARK OFFICE 500 Dulany Street Alexandria, VA 22314-5774 Tel. No.: (571) 272-9038
Read full office action

Prosecution Timeline

Oct 16, 2023
Application Filed
Feb 10, 2025
Response after Non-Final Action
Jan 09, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599609
METHODS OF TREATING FUCHS ENDOTHELIAL CORNEAL DYSTROPHY AFTER DESCEMETORHEXIS
2y 5m to grant Granted Apr 14, 2026
Patent 12582642
Composition for Treating, Improving, and/or Preventing Progression of Bovine Papillomatosis Caused by Bovine Papillomavirus
2y 5m to grant Granted Mar 24, 2026
Patent 12576074
KITS AND METHODS FOR INDUCTION OF CARDIOVERSION IN SUBJECTS WITH ATRIAL ARRHYTHMIAS
2y 5m to grant Granted Mar 17, 2026
Patent 12570650
6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders
2y 5m to grant Granted Mar 10, 2026
Patent 12564559
COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF SOLID TUMORS
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
74%
With Interview (+19.2%)
2y 12m
Median Time to Grant
Low
PTA Risk
Based on 1321 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month